Phadia's fully automated RA (rheumatoid arthritis) test:
This article was originally published in Clinica
Phadia has received US FDA 510(k) clearance to sell what it claims is the first cyclic citrullinated peptide (CCP) antibodies-based test for rheumatoid arthritis (RA) that is fully automated. The EliA CCP assay enables physicians to identify RA very early in the course of the disease and begin, if necessary, an aggressive course of treatment at an earlier stage of the disease when medication is most effective, said the Uppsala, Sweden-based firm. It uses a small sample of blood, which is then analysed for CCP levels through a CLIA-moderate complexity test, which is available on the firm's ImmunoCAP 100 and 250 fully automated laboratory instruments. In its regulatory clearance, the FDA deemed EliA CCP to be substantially equivalent to Axis-Shield's Diastat Anti-CCP test.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.